Emerging Infectious DiseaseImportant note: Information in this article was accurate in March 2002. The state of the art may have changed since the publication date.
Click here to return to Emerging Infectious Disease main menu

Dispatches

HIV Prevalence in a Gold Mining Camp in the Amazon Region, Guyana

Carol J. Palmer,*† Lloyd Validum,‡ Bernard Loeffke,* Harold E. Laubach,* Chris Mitchell,* Rudy Cummings,§ and Raul R. Cuadrado*
*Nova Southeastern University, Ft. Lauderdale, Florida, USA; †BioQuest, Miami, Florida, USA; ‡Woodlands Hospital, Georgetown, Guyana; and §Ministry of Health, Georgetown, Guyana

Emerg Infect Dis 2002 Mar;8(3);330-1


The prevalence of HIV infection among men in a gold mining camp in the Amazon region of Guyana was 6.5%. This high percentage of HIV infection provides a reservoir for the virus in this region, warranting immediate public health intervention to curb its spread. As malaria is endemic in the Amazon Basin (>30,000 cases/year), the impact of coinfection may be substantial.

In Guyana and other South American countries containing large tracts of Amazon jungle, few studies have investigated the prevalence of HIV infection in isolated communities (1). Geographic isolation would lead to low infection rates because of lack of exposure to the disease. In addition, prevalence data on HIV can be negligible even in urban areas. For example, the only reported HIV studies in the Guyanese population have focused on HIV prevalence in commercial sex workers in the capital city of Georgetown (2). No studies have reported the prevalence of HIV in Guyanese men or in the interior Amazon region of the country. We evaluated a group of men living and working in the Amazon region of Guyana to determine the prevalence of HIV infection.

This study was conducted after we obtained Institutional Review Board approvals as well as permission from the Guyanese Ministry of Health and the director of a local Guyanese gold mining camp. Informed consent was obtained from each participant. Typically, men live in gold mining camps for periods of 6 to 8 weeks, working 12-hour days, 7 days per week. At the end of a 6- to 8-week shift, the men rotate out of camp to their homes on the coast for 2 weeks of rest. Mining gold in the Amazon region requires considerable manual labor and long hours working in a hot, humid jungle environment. Salaries paid to gold miners, however, are much better than those of typical jobs in the city. Thus, jobs in the mining industry are attractive, and many men leave their families and work as miners in the jungle for a few years to provide a better standard of living for their families.

Figure
Figure. Typical living quarter for miners in the jungle, Amazon Basin, Guyana.

Click to view enlarged image

Figure. Typical living quarter for miners in the jungle, Amazon Basin, Guyana.

The mining camp in this study was approximately 400 km inland from Georgetown, the capital of Guyana, in the heart of the Amazon region of the country. It was typical of many of the mining camps in the jungle (Figure). Men sleep in rows of 20 to 40 hammocks strung underneath a large tarp-like covering. The tarp coverings are not enclosed, but the men usually sleep under mosquito netting, as malaria infection is a constant problem. Pit latrines are available in the camp as are rainwater shower stalls. Water is obtained from a nearby stream, and a generator provides light in the camp in the evenings. The facility is fenced in and heavily guarded by armed patrols, as gold is stored in the camp from daily operations. The camp is a living facility only as all mining occurs outside the camp itself.

We enrolled almost the entire workforce of the mining camp (n = 216) for participation in this study. Only four declined the free HIV test and were excluded from the analysis. All 216 subjects were Guyanese men (age range 18-35 years). Pre- and post-HIV counseling was completed, and informed consent was obtained from all participants. Seven milliliters of venous blood was obtained from each participant after precounseling was completed. Onsite screening for HIV was completed, and serum was stored on ice and transported for confirmatory testing in a laboratory. Onsite HIV testing was by the Determine (Dainabot, Tokyo, Japan) rapid immunochromatographic test for the qualitative detection of HIV-1/2; in previous field work this test yielded 100% sensitivity and specificity (3). The test required 50 µL of serum, with results available for visual interpretation within 15 to 60 minutes. However, most of the positive samples produced a clearly visible red line within 10 minutes. HIV testing by enzyme-linked immunosorbent assay (ELISA) with Western blot confirmation (Abbott, Abbott Park, IL) was completed on all sera on our return from the jungle. Participants were not given results until confirmatory testing was completed. All participants were notified that results were available by a letter from the collaborating local physician, and all were offered personal counseling when they visited him for their results.

Fourteen (6.5%) of the 216 men were found to have HIV infection by results of both the onsite rapid strip test and subsequent ELISA and Western blot tests. Results obtained with the rapid test performed onsite had 100% agreement with those of the laboratory tests performed after our return.

Results of this small HIV screening study, indicating that 6.5% of men living in this remote camp were HIV positive, suggest enormous potential for further transmission of HIV in Guyana, in both jungle and urban environments. Migration of city dwellers into the Amazon jungle region may increase the risk of transmission of HIV to indigenous people. Conversely, gold miners can become infected with HIV during contact with commercial sex workers in small villages near the mining areas. HIV can then be further transmitted to the miner’s spouse and unborn children on his return to the city. Whether the miners contracted the infection while living in the jungle or whether they entered the region already infected is unclear; however, the high percentage of HIV infection in this population provides a reservoir for the disease in this region and warrants immediate public health intervention to curb its spread.

Intervention is warranted to increase public awareness of HIV in underserved remote jungle and urban regions in Guyana. Rapid HIV screening tests, which can be completed without equipment or ancillary supplies, may provide an important tool for rapid screening and providing immediate feedback to patients. Initial counseling on risk-reducing behavior can be initiated onsite to provide an immediate intervention strategy to prevent the spread of the disease while follow-up testing with a confirmatory HIV test is completed.

Given the high numbers of malaria cases in the Guyana Amazon region, combined with this new evidence of potentially escalating HIV rates, studies are warranted to measure the impact of HIV/malaria coinfection. Reports showing an average of >30,000 cases of malaria per year over the past decade clearly designate this region as having a high rate of endemic malaria (4). Since T-cell and B-cell function, thought to provide a defense against malaria, are both adversely affected at the early stages of HIV infection and continue to deteriorate, this may contribute to higher rates of malaria mortality or more severe malaria symptoms, as the infected person’s impaired immune system is less effective against the invading parasites. Conversely, malaria could exacerbate HIV infection (5), since the already compromised immune system may be overwhelmed by the multiple infection. Thus, HIV/malaria coinfection may contribute to increased rates of illness and death in the Amazon region. Recent studies on HIV/AIDS and malaria in Africa suggest that coinfection with these two diseases has become a concern in Africa (6,7). This problem also merits attention in the Americas so that further research, planning, and interventions will be focused in this region.

Acknowledgment

We thank the Guyana Ministry of Health and Brian Chan-a-Sue and medical team for their assistance in setting up the miner study.

Dr. Palmer is a research professor at the University of Florida. Her primary research interest is in infectious diseases, with special emphasis on emerging diseases, tropical diseases, and field-based research.

Address for correspondence: Carol J. Palmer, Dept. of Pathobiology, College of Veterinary Medicine, University of Florida, 2015 SW 16th Ave., Bldg. 1017, Gainesville, FL 32611-0880, USA; fax: 352-392-9704; e-mail: PalmerC@mail.vetmed.ufl.edu

References

  1. Vicente AC, Otsuki K, Silva NB, Castilho MC, Farros FS, Pieniazek D, et al. The HIV epidemic in the Amazon Basin is driven by prototypic and recombinant HIV-1 subtypes B and F. J Acquir Immune Defic Syndr. 2000 Apr 1; 23(4): 327-31.
  2. Carter KH, Harry BP, Jeune M, Nicholson D. HIV risk perception, risk behavior, and seroprevalence among female commercial sex workers in Georgetown, Guyana. Rev Panam Salud Publica. 1997 Jun; 1(6): 451-9.
  3. Palmer CJ, Dubon J, Koenig E, Perez E, Ager A, Cuadrado RR, et al. Evaluation of the Determine Rapid HIV Diagnostic Test in Honduras and the Dominican Republic. J Clin Microbiol. 1999 Nov; 37(11): 3698-700.
  4. Validum L. Malaria in Guyana. Guyana Health Information Digest 2000;2:4-8.
  5. French N, Gilka CF. HIV and malaria, do they interact? Trans R Soc Trop Med Hyg. 2000 May-Jun; 94(3): 233-7.
  6. Leke RG. The state of immunology in Africa: HIV/AIDS and malaria. Curr Opin Immunol. 2001 Oct; 13(5): 523-7.
  7. Tkachuk AN, Moormann AM, Poore JA, Rockford RA, Chensue SW, V Mwapasa, et al. Malaria enhances expression of CC chemokine receptor 5 on placental macrophages. J Infect Dis. 2001 Mar 15; 183(6): 967-72.

020310
EID8301


All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is appreciated. Emerging Infectious Diseases is published 6 times a year by the National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop D-61, Atlanta, GA 30333, USA. Telephone 404-371-5329, fax 404-371-5449, e-mail eideditor@cdc.gov

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in June 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Feedback/Contact Us.